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Many lines of clinical and experimental evidence indicate a viral role in
carcinogenesis (1-6). Our access to patient plasma, serum, and tissue samples
from invasive breast cancer (N=19), ductal carcinoma in situ (N=13), malignant
ovarian cancer (N=12), and benign ovarian tumors (N=9), via IRB-approved and
informed consent protocols through M.D. Anderson Cancer Center, as well as
normal donor plasmas purchased from Gulf Coast Regional Blood Center (N=6),
has allowed us to survey primary patient blood and tissue samples, healthy donor
blood from the general population, as well as commercially available human cell
lines for the presence of human endogenous retrovirus K (HERV-K) Env viral
RNA (vRNA), protein, and viral particles. We hypothesize that HERV-K
proteins are tumor-associated antigens and as such can be profiled and targeted
in patients for diagnostic and therapeutic purposes. To test this hypothesis, we
employed isopycnic ultracentrifugation, a microplate-based reverse transcriptase
enzyme activity assay, reverse transcription – polymerase chain reaction (RTPCR), cDNA sequencing, SDS-PAGE and western blotting, immunofluorescent
staining, confocal microscopy, and transmission electron microscopy to evaluate
iv

HERV-K activation in cancer. Data from large numbers of patients tested by
reverse transcriptase activity assay were analyzed statistically by t-test to
determine the potential use of this assay as a diagnostic tool for cancer.
Significant reverse transcriptase enzyme activity was detected in 75% of
ovarian cancer patients, 53.8% of ductal carcinoma in situ patient, and 42.1% of
invasive breast cancer patient samples. Only 11.1% of benign ovarian patient and
16.7% of normal donor samples tested positive. HERV-K Env vRNA, or Env SU
were detected in the majority of cancer types screened, as demonstrated by the
results shown herein, and were largely absent in normal controls. These findings
support our hypothesis that the presence of HERV-K in patient blood circulation
is an indicator of cancer or pre-malignancy in vivo, that the presence of HERV-K
Env on tumor cell surfaces is indicative of malignant phenotype, and that HERVK Env is a tumor-associated antigen useful not only as a diagnostic screening
tool to predict patient disease status, but also as an exploitable therapeutic target
for various novel antibody-based immunotherapies.
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Chapter 1 Introduction
For over a century there has been an association between viruses and cancer.
Peyton Rous, building on the work of Bang and Ellerman, announced the isolation of a
filterable cell-free lysate from solid tumor that was capable of transmitting those solid
tumors in chickens in 1910 (1). Mammalian tumor viruses were first discovered by RE
Shope in 1933, with Shope papilloma virus in rabbits (2). As early as 1936, the
physiological effects of mouse mammary tumor virus had been witnessed and described
by JJ Bittner, though he never directly implicated a viral agent in his preliminary report
(3). The discovery of viral proto-oncogenes src, myc, ras, and many others was groundbreaking as their existence helped elucidate a mechanism for viral transformation of
normal tissues into neoplasia (4). Viruses that have been directly implicated in human
cancer include Epstein-Barr virus (EBV) in Burkitt’s and Hodgkin’s lymphoma as well
as nasopharangeal carcinoma, human papilloma virus (HPV16 and 18) in cervical
cancer, human herpesvirus (HHV-8) in Kaposi’s sarcoma, and human T-cell
lymphotrophic virus (HTLV-1) in adult T-cell leukemia and lymphoma (5,6).
One emerging viral instigator of cancer, with growing evidence accumulating
from studies of a variety of human cancers done in our lab and others, is a group of
proteins encoded by genetic artifacts of human endogenous retrovirus (HERV). The
upcoming sections will focus on the structure, organization, and phylogeny of HERV-K
as well as its role in human cancer.
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1.1 Human endogenous retrovirus (HERV)
1.1.1 Origins of HERVs in the human genome
Integration of HERVs into the human genome has yielded stable remnants of
retroviruses that have been determined to constitute nearly 8% of the human genome (7).
Within these integrated elements can be found consensus retroviral gag, pol (coding for
protease and reverse transcriptase), and env (both surface and transmembrane domains)
coding regions. Most families of HERV are degenerate in that their coding regions lack
fidelity due to deletions and nonsense mutations and therefore do not typically produce
functional proteins. In the host, epigenetic regulation is also at work here, modulating
the expression levels of HERV genes through engagement of GC boxes found in the
LTRs flanking viral coding regions (8, 9). The K family of HERV, named for its use of
the lysine tRNA as a primer in replication, is evolutionarily related to type 2
betaretroviruses. HERV-K has been reported to be the youngest of all identified HERV
families and insertions of HERV-K genes with open reading frames can be found across
multiple chromosomes in the human genome (11). Expression of human endogenous
retroviral proteins has been reported in a few diseases (11, 12) though they have not
necessarily been identified as a causative agent and to date compelling evidence for
HERV-K protein involvement in cancer is lacking. In immunohistochemical studies
performed in this lab on human normal and tumor tissue arrays using our anti-HERV-K
Env surface (SU) monoclonal antibodies, levels of expression of HERV-K in tumor
tissue correlate strongly to progression of disease state in cancer patients (13).
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1.1.2 Genomic and Structural features of HERV-K
As endogenous retroviruses are genetic remnants of once-active pathogens that
were once able to infect and integrate their genetic material into host cells, their genome
is highly similar to modern exogenous retroviruses such as HIV. In an intact, mature
betaretroviral virion, the genome exists as a double stranded (+) sense linear RNA
polymer approaching 10 kb in size and forms the viral ribonucleoprotein complex when
in association with the nucleocapsid. Viral protein coding regions are flanked by long
tandem repeats (LTRs) which contain regulatory regions to control expression of viral
genes including gag, pol, and env. The Env protein is composed of SU and TM
(transmembrane) domains and along with Gag and Pol, the integrated proviral genome
of HERV-K coding for these proteins is largely intact as depicted in Figure 1. A mature
betaretrovirus appears as an approximately 100 nm spherical particle under the electron
microscope and bears structural similarity to the particle depicted in Figure 2.
As a retrovirus outside of the host, HERV-K would rely on RT for successful
integration into the host genome subsequent to infection. This enzyme, encoded by the
pol gene, allows the virus to convert its RNA-based genome into DNA via reverse
transcription. If these infection and stable integration events occur in germ cells, the viral
sequences will be transmitted horizontally from parent to progeny; it is commonly held
that this is the mechanism by which HERV retroviral elements exist as they do today in
the human genome. HERV-K is of great interest among all the retroviral elements found
in the human genome because of its relatively recent integration, transcriptional activity,
and existence of open reading frames at various loci across the human genome for many
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of its proteins. Functional envelope and reverse transcriptase proteins of a retrovirus are
prerequisites for virulence; we therefore focused on their detection.
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Figure 1a,b (A) Genomic organization of an example of oncoretrovirus proviral DNA,
and (B) retroviral RNA transcripts. The full-length transcript serves as the RNA genome
and as a messenger RNA for Gag and Gag/Pol polyproteins. The Env is translated from
the spliced transcript. Reprinted from (14) under open access policy of International
Archives of Medicine (BioMed Central).
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Figure 2 Schematic diagram of retroviral virion structure. Reprinted from (14) under
open access policy of International Archives of Medicine (BioMed Central).

6

1.1.3 HERV Classification and taxonomy
A phylogenetic tree has been created for human endogenous retroviruses
as shown in Figure 3. HERVs have been divided into three classes by comparing their
homology to relatives from Retroviridae. HERV class I bears the most resemblance to
modern gammaretroviruses and includes HERV-H, -W and –FRD. Class III HERVs,
showing similarity to spuma-like viruses, include HERV-L and HERV-S. HERV-K, the
focus of this study, is a member of class II and aligns most closely with modern
betaretroviruses such as MMTV. HERVs are commonly named for the host tRNA used
to prime reverse transcription and accordingly HERV-K utilizes lysine tRNA for this
purpose. Sequencing of the primer binding site region of the HERV LTR will tell which
tRNA is used; this naming convention becomes inadequate when two HERVs are found
to use the same tRNA (16).
Most HERVs appear to have integrated long ago, as they are present in the
genomes of Old World primates such as macaques and baboons as well as those of New
World primates. This suggests infection by the oldest pathogenic progenitor of HERV at
least 40 million years ago when these primates diverged. Determinations of when each
HERV infiltrated the human genome rely on comparison of LTR regions both in the
same HERV and between different classes of HERV. This information, along with
estimates of LTR mutation rate over time, can be used to determine the timeframe of
infection for a given HERV.

7

Figure 3 Phylogenetic tree of endogenous and exogenous retroviruses. Representative
unrooted neighbor joining dendrogram based on retroviral Pol sequences. HERV-K is
denoted as HML2 with class II betaretroviruses.
Reprinted from (15) under open access policy of Retrovirology (BioMed Central).
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1.2 Human Cancer and HERV-K
1.2.1 Impact of cancer on women
The World Health Organization has identified cancer as the leading cause of
death worldwide (17). Cancer is destined to kill millions of people a year until a costeffective treatment with broad-reaching efficacy is discovered. Several modern niche
drugs exist which can be incredibly effective in specific subsets of the patient
population, though they typically lack the diverse applicability of traditional, front-line
disease management strategies including surgery, radiotherapy, and chemotherapy.
Worldwide, breast cancer has the highest incidence of any cancer in either men or
women. The rate of incidence for ovarian cancer is significantly lower (84%) than breast
cancer, however the rate of mortality is almost double that of breast cancer (17). The
prevalence and the low long-term survivability of these diseases, the impact on overall
quality of life for those who endure treatment, the great financial and personal stress on
both patients and their families, compounded by the issue of higher overall risk for
developing secondary tumors and other diseases if the patient survives treatment,
warrants identifying meaningful diagnostic screening tools for early detection and safe,
efficacious therapies after diagnosis. Science and medicine must dedicate as many
resources as possible to eradicate these devastating diseases. The current state of
screening, treatment, and long-term management of cancer stands on the back of decades
of hard-learned lessons about the complexity of cancer as a disease that is as unique as
the patient that presents with it. Modern molecular diagnostics have enabled the
development of personalized treatment regimens for cancer patients based on
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characteristics unique to a patient’s individual disease. As with all cancers, the best
chance for tumor cure in breast and ovarian cancer lies in early detection.
1.2.2 HERV-K in breast and ovarian cancer
HERV-K env SU mRNA and HERV-K Env protein has been reported to be
overexpressed in breast and ovarian cancer but absent in normal tissues (13, 18, 19).
HERV-K viral-like particles were also reported in T47D, a commercially available (20),
as well as the blood of lymphoma and breast cancer patients but not in normal samples
(21). Taken together, these reports suggest the HERV-K virus or viral-like particles may
be shed from HERV-K+ malignancies and their presence can be used as to screen for
cancer.
1.2.3 Targeting of tumor markers using antibody-based drugs
There exists among the cancer research community a great interest in identifying
novel tumor-associated and ideally tumor-specific antigens that can be exploited to
fulfill both diagnostic and therapeutic healthcare needs in oncology. Identification and
characterization of novel antigens that are differentially expressed between tumor and
normal tissues is a primary focus of a large contingent of both public and private
research efforts. Clearly, the ultimate goal of this enormous outpouring of effort and
funding is the discovery and validation of marketable drugs for use in the clinic against a
given disease state. If an antigen can be found stably overexpressed in abundance in
neoplastic tissues relative to normal examples, a new potential diagnostic and possibly
therapeutic target will have been found. A limited number of such antigens have been
well-described to date; examples include vascular endothelial growth factor A (VEGFA), oncofetal proteins carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in
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bowel and germ cell tumors, respectively, mucin-1 (MUC-1), and Her2/neu in breast
cancer. Many potential tumor-associated targets present unique pharmacological
challenges including low abundance, high degrees of target sequence variation, and poor
immunogenicity. As a result, development of therapeutic compounds and dosing
strategies thereof showing broad-ranging activity as well as minimized off-target effects
has been a perplexing challenge. Humanized antibodies have been developed against the
above targets (Bevacizumab (VEGF), Clivatuzumab tetraxetan (Muc1), Labetuzumab
(CEA), Tacatuzumab tetraxetan (AFP), and Trastuzumab and Pertuzumab (Her2)) with
the hopes of utilizing these molecules in the clinic. As evidenced by the development of
tetraxetan conjugates above, as well as other immunoconjugates, there is an interest in
modifying antibodies to enable them to deliver active agents directly to tumors .
Examples of antibody-based immunoconjugate drugs that have shown enough
promise to enter clinical trials include those that bear proteinaceous toxins (22, 23),
isotopes (24), chemotherapy drugs (25), and prodrugs (26). Along with current studies
using existing chimeric or humanized antibodies recognizing the well-defined tumor
markers mentioned above, new targets have emerged as our understanding of tumor cells
induction, growth, and metastasis grows. Through identification and characterization of
novel tumor-associated antigens such as HERV-K Env, we hope to increase the
availability of safe and efficacious reinforcements in the supply of current clinical
armaments.
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1.3 Hypothesis and specific aims
Reports of expression of human endogenous retroviral mRNA and protein in
tissues isolated from cancer patients and the lack of these viral markers in normal tissues
(13, 18) prompted us to attempt to identify HERV-K particles shed from HERV-K+
tumors into the blood circulation of cancer patients with the ultimate goal of identifying
mature, infectious HERV-K virions. Based on these previous findings, we hypothesize
that HERV-K viral proteins RT and Env SU are tumor-associated proteins, the
presence of which can be exploited for diagnostic and therapeutic purposes. We
tested this hypothesis by carrying out the following two specific aims.
Specific aim 1. To determine the prevalence of reverse transcriptase enzyme activity in
cancer patient plasma samples compared to normal donors as a potential diagnostic
marker.
Specific aim 2. To determine the potential of antibodies recognizing HERV-K Env SU
for use as diagnostic and/ or therapeutic agents.

12

Chapter 2 Materials and Methods

2.1 Cell lines, clinical samples, and animals
Human breast cancer cell lines T47D, ZR-75-1, and SK-BR-3 were purchased
from ATCC (Rockville, MD) and cultured as per ATCC recommendations. The human
pancreatic cancer cell line Panc-2 was also obtained from ATCC and cultured as per
ATCC recommendations. The breast adenocarcinoma cell line MDA-MB-231 as a kind
gift from Dr. Michael Rosenblum (M. D. Anderson Cancer Center, Houston, TX) and
was cultured in RPMI-1640 media containing 10% FBS, 100 U/ml penicillin, and 100
μg/ml streptomycin. The breast adenocarcinoma cell line MCF-7 was a kind gift from
Dr. Melinda Hollingshead (Developmental Therapeutics Program, Division of Cancer
Treatment and Diagnosis, NCI) and was cultured in RPMI-1640 media containing 10%
FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin. The fibrocystic breast diseasederived cell line MCF-10A was a kind gift from Dr. Robert Pauley (Karmanos Cancer
Institute, Detroit, MI) and was cultured in Dulbecco’s Modified Eagle Medium : Ham’s
Nutrient Mixture F12 (DMEM:F12) medium containing 5% horse serum, 100 U/ml
penicillin, 100 μg/ml streptomycin, 10 μg/ml insulin, and 20 ng/ml epidermal growth
factor. MCF-10AT, the H-Ras-transformed variant of MCF-10A, was a generous gift
from Dr. Fred Miller (Wayne State University, Detroit, MI) and was cultured in the same
media formulation as MCF-10A detailed above. Murine hybridoma lines 6h5 and 6e11,
producing monoclonal antibodies against HERV-K Env SU, were produced under
contract with Auburn University Hybridoma Facility, Auburn AL.
With informed consent, patient plasma, sera, and tissues were obtained from
human patients through Institutional Review Board (IRB)-approved protocols in place at
13

M.D. Anderson Cancer Center, Houston, TX. Gender-matched healthy donor buffy
coats were purchased from Gulf Coast Regional Blood Center, Houston, TX.
6-8 week old female Balb/c (National Cancer Institute, Frederick, MA) mice
were used for the generation of ascites fluid from which the monoclonal antibodies 6h5
and 6e11 were purified. 8 week old NOD-SCID gamma mice, a kind gift from Dr. Dean
Tang (M. D. Anderson Cancer Center, Smithville TX), were used for MDA-MB-231 and
Panc-2 xenograft studies.
2.2 Monoclonal antibody production
Production of ascites containing monoclonal antibodies were carried out under an
IACUC-approved ACUF. Hybridoma lines were maintained in suspension culture in
RPMI-1640 including 1mM oxaloacetate, 0.45 mM pyruvate, 0.2 U/ml insulin, 100 μM
hypoxanthine, 16 μM thymidine, and 10% FBS in T75 flasks. The cells were treated
with 30 μg/ml mitomycin C for 30 minutes and washed twice in PBS immediately prior
to injection.
20 Balb/c mice were primed using 0.5 ml of pristane administered to the
peritoneal cavity 2 weeks before 5x106 mitomycin c-treated hybridoma cells were
injected ip. At the onset of edema, ascites was drained from the peritoneal cavity by 18
gauge needle; this was repeated twice as needed over the course of a few weeks to
relieve accumulated fluid. Animals were sacrificed by CO2 asphyxiation and subsequent
cervical dislocation upon completion of three ip taps. Harvested ascites was centrifuged
at 500 xg for 5 minutes to remove cells and coagulates. Ascites generated from the same
hybridoma were collected, pooled, and thoroughly admixed. 10 ml aliquots of this
clarified supernatant were frozen at -80° C for future purification.
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Antibody was purified by thawing a 10 ml aliquot of ascites fluid on ice then
diluting it 1:1 with cold PBS. This diluted ascites was centrifuged at 500 xg at 4° C to
remove cryoprecipitates; the supernatant was retained and an equal volume of saturated
ammonium sulfate was added drop-wise while mixing. This preparation was incubated
overnight at 4° C with continuous mixing. The next day the sample was centrifuged at
10,000 xg for 30 minutes at 4° C to pellet precipitated proteins. This pellet was
resuspended in PBS and the ammonium sulfate precipitation process was repeated once
more as described above. The final pellet of precipitated protein was resuspended in PBS
and clarified with a 0.45 μ CA filter. This clarified, double salt-cut ascites was purified
on an ÄKTA FPLC using a Protein G HP affinity resin column (GE Healthcare);
antibody was eluted in 0.1 M glycine pH 2.5 directly into fraction collection tubes preloaded with one-tenth volume 1 M Tris base pH 9 to immediately neutralize the low pH
of the elution buffer. Protein-containing fractions, as determined by on-line 280 nm UV
absorbance monitoring, were pooled and dialyzed overnight against PBS at 4° C using a
Slide-a-Lyzer 3 kDa MWCO dialysis cassette (Pierce).
Antibody preparations intended for cell dosing were further purified using
Detoxi-Gel polymixin B affinity resin (Pierce) to remove bacterial lipopolysaccharides
(endotoxin). Total protein concentration was determined by UV spectrophotometry at
280 nm. All antibodies were sterilized using 0.2 μ SFCA filtration and aliquots of
purified antibody stored in -80° C for future use.
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2.3 Antibody isotype determination
To determine the isotype of 6h5 and 6e11 monoclonal antibodies, 100 μl of
confluent hybridoma culture media was tested using a mouse antibody isotyping test
strip kit (AbD SeroTec, Raleigh, NC) per the manufacturer’s instructions.
2.4 Antibody conjugation to AuNP
The isoelectric point of 6h5 was determined by isoelectric focusing. One
mg of 6h5 was dialyzed against distilled water pH 7.4 overnight at 4º C. 500 µg of
dialyzed 6h5 was incubated with 50 ml of 5 nm or 30 nm colloidal gold (Ted Pella,
Redding, CA) at pH 7.4 with gentle agitation for 15 minutes at room temperature. The
conjugate was loaded into a 30 ml dialysis cassette (Slide-A-Lyzer; Pierce, Rockford,
IL), wrapped in cheesecloth, and left buried in drying resin (Silica gel Rubin; SigmaAldrich) overnight. This pre-concentration process was repeated until the sample volume
was approximately 3 ml. A 30-ml column of Sephacryl S-500-HR (GE Healthcare) was
prepared and unincorporated label was removed by size-exclusion chromatography
using ÄKTA FPLC. Fractions containing mAb-AuNP conjugate as determined by online
A280 monitoring were pooled, stabilized with 0.1% polyethylene glycol 1000, and
concentrated using 3kDa molecular weight cut off centrifugal concentrators (Amicon
Ultra; Millipore, Billerica, MA).
2.5 HERV-K+ xenograft labeling with 6h5-AuNP conjugate
Murine xenograft models were carried out under an IACUC-approved ACUF. 8
week old NOD-SCID gamma mice were inoculated sc in the right flank with 5x106
MDA-MB-231 or Panc-2 tumor cells. Once tumors reached 1cubic centimeter, 25μg (by
protein) of 6h5-AuNP conjugate (5 nm AuNP for MDA-MB-231 and 30 nm AuNP for
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Panc-2) were administered iv via the caudal vein. 24 hours after dosing, the mice were
euthanized and tumors were excised. The tumor tissue was minced and fixed in 2%
paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer pH 7.4
overnight. The tissue was counterstained in 2% aqueous uranyl acetate (UA) for 1 hour,
washed, and post-fixed in OsO4-KFeCN for 2 hours in the dark. The tissue was then
dehydrated through increasing concentrations of ethanol, then with acetone previously
dehydrated using a water-sequestering molecular sieve (type 3A, Sigma). The sample
was then infiltrated with Spurr’s low viscosity resin (Structure Probe Incorporated, West
Chester, PA) and cast into blocks by heat polymerization, which was accomplished by
baking for 2 days at 80° C. Thin sections were cut with an Ultra 35 diamond knife
(Diatome, Hatfield, PA)-equipped Ultracut UCT (Leica) and captured on pre-cleaned
bare copper grids. Section were imaged on a Spirit TEM (Tecnai, Hillsboro, OR)
operating at 80 kv.
2.6 Synthetic HERV-K Env SU antigen production
An open reading frame for HERV-K Env SU was cloned into the bacterial
expression vector pGEX-6p1and transformed into chemically competent E. coli BL-21
(DE3). Subclones were screened for soluble fusion protein expression; clone K10g was
chosen, which expresses a full-length HERV-K Env SU bearing an N-terminal GST
affinity tag.
The clone K10g was streaked onto a fresh LB-agar plate containing 50 μg/ml
ampicillin and incubated overnight at 37° C. A single colony was picked and used to
inoculate a 3 ml starter culture of K10g in Super Broth (35g tryptone, 20g yeast extract,
5g NaCl in dH2O) containing 50 μg/ml ampicillin overnight at 37° C with 250 rpm
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agitation. This starter culture was used to inoculate 1 L of Super Broth including 1 mM
MgSO4 and 50 μg/ml ampicillin in baffled flasks with 250 rpm shaking. After reaching
OD600 of 1.0 (where the maximum OD600 of the culture system is ~1.5), the culture was
induced with 1 mM IPTG at 18° C overnight with continued shaking at 250 rpm. The
culture was harvested in a Sorvall Evolution RC superspeed centrifuge equipped with a
SLA-3000 rotor at 6,000 xg for 15 minutes.
Bacterial culture pellets were resuspended in 3 ml per gram of wet pellet weight
of PBS + 1 mM EDTA + 1 mg/ml lysozyme and incubated on ice for 1 hour. The
digested pellet was sonicated 4 times total, 25 ml at a time on ice using four 10 second
cycles at ~100 watts power output. Foaming was avoided and the sample was allowed to
cool for 1 minute between cycles. Lysis was confirmed by drastic reduction in viscosity
and partial clarification of the sonicated sample. This material was centrifuged for 30
minutes at 50,000 xg at 4° C and further clarified with a 0.45 µ SFCA filter.
The clarified lysate was applied to a glutathione resin column connected to an
ÄKTA FPLC. Samples were eluted using freshly-prepared 10 mM reduced glutathione
in 50 mM Tris base pH 8. Protein-containing fractions, as determined by on-line A280
monitoring, were pooled and dialyzed overnight against a 400-fold excess of PBS with
constant stirring at 4˚ C using a Slide-a-Lyzer 3kDa MWCO dialysis cassette (Pierce).
Aliquots of all purified materials were stored in -80° C for future use.
2.7 Antibody kinetic and concentration analysis
Biacore technology exploits the phenomenon of SPR to analyze biomolecular
interactions. All Biacore experiments were carried out at 25° C and used HBS-EP
running buffer. Calibration-free concentration analysis (CFCA) was performed on the
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Biacore X100 biosensor platform which detects binding of the antibody in solution
flowing over a surface of immobilized K10g antigen. K10g immobilization conditions
were scouted by injecting 30 nM K10g in 10 mM sodium acetate at pH 4, 4.5, 5, and 7
over a naïve CM5 chip surface. Regeneration scouting was performed using 300 nM 6h5
to test four different regeneration conditions. Five cycles of binding and regeneration
were carried out using 30 second injections of either 2 M MgCl2 in 5 mM glycine pH 2,
5 M NaCl pH 7, 100% ethylene glycol, or 10 mM NaOH pH 12 and both baseline and
response data was plotted.
For CFCA, a high degree of ligand density immobilization is required. Two flow
cells of a CM5 chip were activated using 50 mM EDC + 200 mM NHS in water for 2
minutes. The test flow cell had ~7500 RU of K10g immobilized on the surface; once
adequate ligand was bound, unreacted immobilization sites were quenched with 1 M
ethanolamine pH 8.5 for 4 minutes. On the same chip a blank control flow cell was
prepared where no ligand was immobilized (activation and quenching only). Dilutions of
analyte were prepared at 1:1, 1:10, 1:100, and 1:1000 to span a wide range of
concentrations. These dilutions were simultaneously injected in duplicate across both the
K10g ligand and blank flow cell surfaces at 10 μl/min and 100 μl/min to determine the
effect of flow rate on mass transport limitation. Our molecular diffusion constant (D)
was 5e-11 m2/sec for 6h5 and 6e11 in water at 20˚C. The resulting SPR sensorgrams
were then analyzed using Biacore X100 Evaluation software to determine the active
analyte concentration. These concentrations as determined by CFCA were used in
subsequent kinetic analysis as well as other experiments. Fitting statistics are a crucial
part of interpreting data generated by SPR; for CFCA experiments a χ2 value is
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calculated by the evaluation software to indicate “goodness-of-fit” to ideal binding
equations. Ideally, χ2 values for quality data should be less than 5% of the Rmax of the
slower flow rate. Another metric generated by the evaluation software is a QC ratio,
which ideally should be close to 0.2 for confident results.
In order to obtain kinetic binding constants for 6e11 and 6h5 against the
recombinant cognate antigen K10g, we also employed the Biacore X100 platform. A
CM5 chip was docked to the Biacore X100 instrument and 30 μl/min flow was initiated.
Two flow cells of a CM5 sensor chip were activated using 50 mM EDC + 200 mM NHS
in water for 2 minutes. Approximately 200 RU of K10g in 10 mM sodium acetate pH
4.5 was immobilized onto the test flow cell. Once 200 RU of K10g ligand was
accumulated on flow cell two, both flow cells were quenched by injecting 1 M
ethanolamine pH 8.5 over both surfaces for 4 minutes. The chip was primed 5 times
before the binding experiment was carried out. A series of duplicate antibody
concentrations of 0, 3, 6, 12, 24, and 48 nM were then injected simultaneously over both
the test and control flow cells.
SPR sensorgrams from ligand-immobilized flow cells was normalized by
subtracting the signal from the blank flow cell; resulting data generated from these
kinetic experiments were fitted to a 1:1 Langmuir thermodynamic binding model in the
Biacore X100 evaluation software. The Evaluation software reported thermodynamic
constants as well as statistical fitting parameters from these fitted curves; χ2 values at or
less than 1% of Rmax are considered ideal and indicate a good fit to the chosen binding
model.
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2.8 Isopycnic (density gradient) fractionation
To identify HERV-K viral components in human plasma, heparinated blood was
overlaid on Histopaque 1077 (Sigma, St. Louis, MO) density gradient media and
centrifuged at 400 xg for 30 minutes at room temperature. The plasma layer was
retrieved and 10 ml were used for isopynic separation of viral particles. Isolation of
viral particles was carried out using OptiPrep® iodixanol (AxisShield, Norton, MA)
density gradient medium by diluting 10 ml of plasma into 28 ml total volume with PBS.
This sample was loaded into a polyallomer ultracentrifuge tube and 4 ml of a 50%
solution of iodixanol in PBS was underlaid. This sample was centrifuged at 111,800 xg
(average) for 90 minutes in an AH629 swinging bucket rotor in a Sorvall UltraPro 80
ultrarcentrifuge. After this pre-concentration step, the top 22 ml of media was discarded
and the remaining sample was mixed with the underlying iodixanol cushion to give a
final sample concentration of approximately 20% iodixanol. The samples were the
loaded into crimp-top polyallomer tubes at centrifuged for 5 hours at 314,543 xg
(average) in a T865.1 fixed-angle rotor. Samples were carefully removed from the rotor
to avoid disturbing the gradient and each tube was punctured at the top and bottom. 200
μl fractions were drained from the bottom of the tube in order of decreasing density and
collected into sample tubes. The remainder of the sample in the gradient was collected
into 2 ml fractions also in order of decreasing density and archived. Viral particles
isolated by isopycnic fractionation were kept at -20° C for further analysis.
Isopycnic fractionation of viral particles from conditioned cell culture media
from MCF-7 was carried out in the same way as plasma described above, only 28 ml of
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undiluted media was used in lieu of diluted plasma and 6 fraction preparations were
pooled and analyzed.
2.9 Patient tissue viral particle isolation
100 mg of snap-frozen patient tissue was homogenized using a conical mortar
and pestle in 1 ml of RPMI-1640 + 10% FBS. This triturate was then passed through a
0.45 μ SFCA filter, divided into aliquots, and stored frozen at –80° C for future analysis.
These samples were used only in RT-PCR experiments.
2.10 Reverse transcriptase assay
Patient plasma density gradient fractions were thawed and mixed thoroughly. 50
μL was removed and dissociated with 10 mM Tris base pH 8.0 + 0.2 mM DTT + 0.2%
Igepal CA-630 with constant agitation at room temp for 1 hour. Dissociated viral
particles were assayed for RT activity using EnzChek RT Assay (Invitrogen, Carlsbad,
CA) as per manufacturer’s instructions. This assay uses RT enzyme from the sample to
carry out reverse transcription on a pre-annealed poly (A) primer and oligo dT template.
The resulting RNA:DNA heteroduplexes are stained with PicoGreen and the plate is
read in fluorescence mode with a Victor V plate reader (Perkin Elmer, Waltham, MA).
2.11 RT-PCR
Viral RNA was purified from 50 μl of each tested gradient fraction using the
MinElute Viral RNA purification kit (Qiagen). vRNA was eluted in 50 μl of buffer
AVE; 5 μl of this eluate was used for RT-PCR using K10 (type 1) and K22 (type 2)
primers. Total RNA from the HERV-K+ malignant breast adenocarcinoma cell line SKBR-3 (ATCC, Manassas, VA) was used for K10 and K22 positive control. Template-free
negative controls were included as well to test for contamination of reaction
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components. An aliquot of each viral RNA was also treated with 0.1 mg/ml RNase A for
1 hour at 37˚ C and setup as a parallel reaction with K10 primers to determine the
contribution of genomic DNA contamination to the PCR result. Subsequent RT-PCR
was carried out using the OneStep RT-PCR kit (Qiagen) to amplify Type 1 and Type 2
HERV-K Env SU vRNAs using K10 sense (5'-AGAAAAGGGCCTCCACGGAGATG3'), K22 sense (5'-GTATGCTGCTTGCAGCCTTGATGAT-3’), and K10 antisense (3'ACTGCAATTAAAGTAAAAATGAA-5') primers. Type 1 and type 2 HERV-K
amplicons are both generated using the same antisense primer. 5 μl of each vRNA was
used as the template in each reaction with a final reaction volume of 18 μl. Hot start PCR
was carried out on a DNA Engine (PTC-200, Bio-Rad) thermocycler using the following
program: 50° C for 30 minutes (reverse transcription reaction), 95° C for 15 minutes
(required for activation of HotStart Taq polymerase), then 35 cycles of 30 seconds at
94° C, 30 seconds at 55° C, and 1 minute at 72° C. A final extension for 10 minutes at
72° C completed the RT-PCR. RT-PCR reactions were resolved by 1% agarose gel
electrophoresis in TAE (40 mM Tris-acetate + 1mM EDTA) buffer; once the reaction
was complete, 6x gel loading buffer was added directly to the reaction, the entire sample
was loaded into the gel and resolved by electrophoresis for 75 Vhr. Gels were stained in
TAE buffer containing 0.5 μg/ml ethidium bromide for 1 hour with gentle agitation and
imaged on a gel documentation system using UVB transillumination (Gel Doc 1000,
Bio-Rad). Amplicons of interest were excised from the gel under brief UV
transillumination and purified from the gel slice using QIAquick Gel Extraction kit
(Qiagen), with elution in 10 mM Tris-Cl pH 8.5. Concentration was determined by
NanoDrop (ND-1000, NanoDrop Technologies Wilmington, DE) and submitted for
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unidirectional sequencing to the Science Park Research Division – Center for Research
on Environmental Disease SPRD-CRED Molecular Biology Core in the Molecular
Carcinogenesis Department at MD Anderson Cancer Center using the 5’ PCR primer.
Sequencing results were aligned to known HERV-K sequences in PubMed using NCBI’s
BLAST.
2.12 1-D SDS-PAGE and Western Blot
For K10g, a 10% acrylamide denaturing SDS-PAGE was carried out. 10 μg of
purified protein was heated in reducing Laemmli sample buffer at 95˚ C for 10 minutes
before loading onto the gel. For 6h5 and 6e11, 10 μg of purified antibody were heated in
non-reducing Laemmli sample buffer at 95° C for 5 minutes before loading onto a 4%
SDS-PAGE gel. A pre-stained molecular weight reference marker was included on all
SDS-PAGE experiments. Samples were resolved by electrophoresis in Laemmli running
buffer for 100 Vhr. At this point gels bound for coomassie stain were removed and fixed
in destain solution (10% acetic acid, 40% dH2O, and 50% methanol) for 30 minutes.
The gels were then stained for 10 minutes in a coomassie R250 solution (50% methanol,
40% dH2O, 10% acetic acid + 0.25% coomassie R250) that was preheated to 65˚ C and
subsequently bathed in destain solution until protein bands became clearly visible and
the level of background stain was acceptable. These coomassie-stained gels were dried
onto filter paper using a SGD 4050 gel dryer (Thermo-Savant, Waltham MA) at 65° C
for 3 hours. Samples bound for western blotting were removed, sandwiched in the
transfer cassette of the Mini-Protean 2 wet blotting apparatus (Bio-Rad) between filter
paper and adjacent a piece of 0.2 μ PVDF membrane prewetted with pure methanol and
equilibrated in transfer buffer. The transfer was carried out at 60 mA overnight at 4˚ C.
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The next day the membranes were removed, blocked in PBS + 0.2% Tween 20 + 3%
BSA for 1 hour at room temp with gentle agitation, and probed with the indicated
antibodies.
For western blot of total cell lysates, cells were cultured to 95% confluence in the
media formulation recommended by ATCC. Cells were washed in PBS, resuspended in
1% CHAPS + protease inhibitor cocktail (Roche, Indianapolis, IN) and frozen overnight
at -80° C. Total protein concentration of clarified lysates was determined by Bradford
assay and 50 μg of lysate were boiled in Laemmli sample buffer and resolved by 10%
SDS-PAGE along with a lane of Kaleidoscope Precision Plus ladder (BioRad, Hercules,
CA). PVDF was pre-wetted in methanol and equilibrated in Laemmli transfer buffer;
samples separated on the SDS-PAGE gel were wet-transferred onto this conditioned
PVDF membrane overnight at 60 mA at 4° C. The next day membranes were blocked
with 3% BSA in TBS+0.2% tween 20 for 1 hour at room temp with gentle agitation. 1
μg/ml 6h5 was added for 1 hour in blocking buffer and rinsed thoroughly in TBS-0.2%
tween 20. 1 μg/ml anti-mouse IgG-HRP conjugate was added for 1 hour at room temp in
blocking buffer and washed thoroughly in wash buffer, followed by TBS only. ECL
reagent (Western Lightening Plus, Perkin Elmer) was added to the membrane and
exposed for various amounts of time to Biomax light ECL imaging film (Kodak,
Rochester, NY). Films were developed using standard developer and fixer chemistry
(Merry Xray, San Antonio, TX).
Patient plasma fractions were prepared for western blotting by
chloroform:methanol precipitation. To 25 μl of each plasma fraction, 100 μl of methanol
was added and the sample was vortexed for 5 seconds. 25 μl of chloroform was then
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added and vortexed again. 75 μl of dH2O was then added and vortexed. The sample was
then centrifuged at 15,000 xg for 2 minutes and the supernatant discarded. 100 μl of
methanol was added to the pellet, vortexed again, and centrifuged at 15,000 xg for 2
minutes. The supernatant was discarded and the remaining solvent was purged from the
sample by drying the pellet in a SpeedVac (Thermo-Savant) for 10 minutes. The pellet
was dissolved in Laemmli sample buffer modified with 6 M urea, 1% CHAPS, and 50
mM DTT. Samples were resolved by 10% SDS-PAGE, transferred onto PVDF
membranes, and blocked with 5% non-fat milk in TBS + 0.2% tween 20 (BLOTTO).
The blocked membranes were probed with 10 μg/ml 6e11 for 1 hour at room
temperature, washed in TBS + 0.2% tween 20 (TBS-T), and probed with 10 μg/ml antimouse IgG-HRP. After thorough washing in TBS-T, the membranes were rinsed in TBS,
and ECL reagent (Western Lightening Plus, Perkin Elmer) was added to the membrane
and exposed for various amounts of time to Biomax light ECL imaging film (Kodak,
Rochester, NY). Films were developed using standard developer and fixer chemistry
(Merry Xray, San Antonio, TX).
2.13 Anti-HERV-K Env SU Antibody Internalization Assay
Antibody internalization assays were performed by culturing adherent cells on
pre-cleaned #1.5 glass coverslips in 6 well plates to 90-95% confluence. The cells were
rinsed with HEPES-buffered saline (20 mM HEPES + 150 mM NaCl pH 7.4) to remove
media components. 10 μg/ml 6e11 or isotype-control mIgG2a (R&D Systems,
Minneapolis, MN) in binding buffer (HEPES-buffered saline + 3% BSA pH 7.5) on ice
for 1 hour in the dark to minimize phototoxicity related to light-induced HEPES
degradation. The cells were then rinsed in fresh binding buffer and room-temperature
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cell culture media was added back onto the cells. The plates were placed back in the 5%
CO2 incubator for 2 hours at 37° C. After 2 hours of internalization, cells were fixed in
4% paraformaldehyde in PBS pH 7.4 at room temperature overnight. The next day cells
were washed in PBS, permeabilized for 20 minutes in 0.2% Triton X100 in PBS with
gentle agitation, and quenched with 50 mM NH4Cl in PBS pH 7.5 for 30 minutes at
room temperature. Cells were rinsed with PBS and blocked with 1% BSA in PBS +
0.2% Tween 20 for 1 hour at room temperature. Polyclonal anti-mouse IgG (H+L)
(Pierce, Rockford, IL) was labeled with AlexaFluor 488 CASE (Invitrogen) structureas
described by the manufacturer. Anti-mouse IgG-AlexaFluor 488 was incubated with
cells for 1 hour at room temperature; cells were then counterstained with 100 nM DAPI
for 5 minutes and rinsed twice with PBS + 0.2% Tween 20. Stained cells on coverslips
were mounted to standard glass slides in 90% glycerol in PBS, set in place with clear
fingernail varnish, and allowed to dry before imaging.
The samples were imaged using a Zeiss Meta 510 Confocal Laser Scanning
Microscope equipped with a 63x oil immersion objective; the pinhole aperture was set at
1 airy unit for each channel. Images were captured sequentially using 405 nm excitation
for DAPI and 488 nm excitation for AlexaFluor 488. Pinhole aperture diameters were
0.6 μ for the 405 nm channel and 0.7 μ for the 488 nm channel. Tile scan images are a
montage of 5x5 scan areas. For the scan speeds utilized, the pixel dwell time was
approximately 1.5 milliseconds. 8 bit confocal images were acquired with sequential
frame switching at 512 x 512 pixel resolution.
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2.14 Transmission Electron Microscopy
Select density gradient fractions from patient plasma showing high RT enzyme
activity were prepared for imaging by TEM by 1:100 dilution with PBS. 300 mesh
carbon-coated nickel grids (Structure Probe Incorporated) which were prepared by glow
discharge in air for 1 minute at 50 mA in an EMITech X100 plasma discharge unit.
Diluted plasma fractions were adsorbed onto the glow-discharged grids for 5 minutes;
excess liquid was wicked away with a piece of clean Whatman #1 paper (Whatman,
Piscataway, NJ). 2% aqueous uranyl acetate (Structure Probe Incorporated) was
prepared by thorough vortexing of the counterstain and centrifugation at 20,000 xg for
10 minutes to pellet undissolved uranyl acetate. The grids were counterstained by
floating them on a droplet of 2% aqueous uranyl acetate for 3 minutes. Excess stain was
wicked away with Whatman #1 paper as described above and the grids were imaged on a
Tecnai Spirit TEM operating at 80 kv.
2.15 Statistical Analysis
Patient plasma fraction reverse transcriptase assay results were binned into
benign and malignant disease categories for ovarian patient samples and into invasive
and in situ categories for breast patient samples. Pooled plasma fraction reverse
transcriptase enzyme activity results were designated as either positive or negative for
RT enzyme activity; a patient considered as having a positive response showed reverse
transcriptase activity over 700,000 RFU in any pool tested. These results were tabulated
by disease status and percent RT positive was calculated. These binned data were then
analyzed by t-test to determine statistical significance of differences in RT activity
between samples obtained from malignant tumor patient plasma, benign tumor patient
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plasma, and normal donor plasma samples. A significant result obtained a p-value of less
than 0.05 by t-test.
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Chapter 3 Results

3.1 Monoclonal antibody production
In order to characterize the expression of HERV-K Env SU antigen in our
samples, we needed a consistent source of monoclonal antibody that could recognize the
viral antigen with high sensitivity and specificity. Production of murine monoclonal
antibodies by ascites proved to be an effective strategy from both an economic and
product quality perspective. When primed with pristane 7-10 days prior to hybridoma
introduction, mice bearing 5x106 hybridoma cells ip will begin to form ascites in the
abdomen within 2-4 weeks. Our ACUF provides for 3 taps, which occur within 1-2
weeks with the rapid advancement of both liquid and solid portions of the ascites. It is
common to retrieve 10 ml of ascites per animal over the course of tapping in a successful
production, which yields approximately 1 mg/ml final affinity purified antibody with
activity greater than 50% (the best lot of 6e11 achieved 80% activity). After two rounds
of salt-cutting and affinity purification using protein G resin on ÄKTA FPLC, we enjoy
single bands by non-denaturing SDS-PAGE from the final dialyzed eluate as indicated in
Figure 4. When tested using AbD Serotec’s murine antibody isotype kit, both 6h5 and
6e11 tested as IgG2a.
3.2 Recombinant HERV-K Env SU-GST production
As attempting to purify HERV-K Env from natural sources would be a laborious
and time-consuming effort at best, we elected to produce a recombinant form of this
viral antigen for our studies. Yields of soluble antigen improved with the following
modifications beyond the generalized GST fusion protocol suggested by GE Healthcare:
1) amending the media with MgSO4, culturing in baffled shaker flasks, and using the
30

Figure 4 Non-denaturing SDS-PAGE of purified and dialyzed monoclonal antibodies.
Reprinted from (27) with permission from Oxford University Press.
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richer Super Broth media formulation allowed the culture system to support much higher
densities of E. coli, allowing induction at a higher culture density, 2) inducing at 18° C
overnight instead of the typical 37° C for several hours probably slowed down protein
folding kinetics enough to allow for more correctly folded protein per liter of culture and
therefore greater soluble yields, and 3) using a combination of lysozyme, EDTA, and
sonication (enzymatic, chemical, and mechanical) treatments to maximize lysis of the
induced culture after harvest. Figure 5 depicts a coomassie-stained 10% SDS-PAGE and
western blot of a representative batch of K10g after affinity purification with glutathione
resin on ÄKTA FPLC. The single band at ~67 kDa is evident and the preparation is
essentially pure. Four liters of induced shaker flask culture prepared in the manner
described can yield several milligrams of soluble K10g, which must be dialyzed into
PBS, portioned into aliquots, and stored frozen at or below -20° C to avoid aggregate
formation.
3.3 Total cell lysate western blot
Total protein lysates were made from several malignant cancer cell lines as well
as MCF-10A and MCF-10AT. 50 μg of each lysate was resolved by SDS-PAGE,
transferred to PVDF membrane, and probed for either HERV-K Env SU or ACTB using
6h5 or anti-actin primary and anti-mouse IgG-HRP secondary antibodies. All malignant
cell types tested were positive for HERV-K Env SU. MCF-10A, an immortalized cell
line derived from a patient with fibrocystic breast disease, was negative for HERV-K
Env SU. An H-Ras-transformed variant of MCF-10A, MCF-10AT, showed intermediate
expression of HERV-K Env SU, as shown in Figure 6.
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Figure 5 Production of recombinant HERV-K Env SU-GST (K10g). (A) Coomassiestained SDS-PAGE gel, reprinted from reference (27) with permission from Oxford
University Press. (B) Western blot of K10g probed with 6h5.
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Figure 6 Western blot of HERV-K+ malignant breast cancer and HERV-K- breast cell
lysates. Reprinted from reference (27) with permission from Oxford University Press.
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3.4 Antibody kinetic and concentration analysis
Thermodynamic affinity (KD) as well as other kinetic binding constants were
determined for each monoclonal antibody recognizing K10g using surface plasmon
resonance on the Biacore X100 platform. We chose to use CM5 sensor chips, as this
chip format is both the most flexible and cost-effective. A low ligand density surface,
approximately 200 RU, was prepared for the kinetic analyses and a high ligand density
surface, approximately 7500 RU, was prepared for CFCA experiments. Zero ligand
density flow cells, which were activated with EDC + NHS then directly quenched with
ethanolamine, were also created as control surfaces to determine levels of non-specific
interaction and bulk solvent contribution for data normalization purposes during curve
fitting and evaluation in the Biacore X100 evaluation software.
CFCA results varied on a per lot basis and representative lots of 6h5 and 6e11 are shown
in Figure 7a and b. The KD values for 6h5 and 6e11 were 1.46 nM and 1.87 nM,
respectively, and normalized sensorgrams along with fitted curves are shown in Figure
7c and d. These affinities are optimal for murine monoclonal antibodies, near the limit
expected for this type of molecule, and so fulfill the sensitivity requirement for robust
diagnostic agents. Lack of significant binding of either antibody to the ligand-free
control flow cell addresses and mitigates specificity concerns. Statistical analyses of the
kinetic evaluations generated by the Biacore X100 evaluation software are presented in
Table 1.
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Figure 7a-d – Anti-HERV-K Env SU antibody CFCA (A,B) and kinetic (C,D) SPR
sensorgrams. Black lines indicate fitting curves generated by Biacore X100 evaluation
software.
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CFCA
Antibody

Active Concentration (M)

QC ratio

Chi² (RU²)

6h5

9.50E-06

0.299

0.14

6e11

5.10E-07

0.099

0.045

Kinetics
Antibody

Ka (M-1 s-1)

Kd (s-1)

KD (M)

Chi² (RU²)

U-value

6h5

2.43E+05

3.54E-04

1.46E-09

0.073

5

6e11

4.18E+05

7.82E-04

1.87E-09

0.297

3

Table 1 – Anti-HERV-K Env SU antibody CFCA results and kinetic constants with
fitting statistics generated by Biacore X100 evaluation software.
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3.5 Patient plasma gradient fraction analysis
Reverse transcriptase (RT) enzyme activity in a diverse selection of patient plasma and
normal donor density gradient fractions was assayed using the EnzChek RT kit
(Invitrogen), which uses a non-radioactive reporter and relies on reverse transcriptase
from the test sample generating RNA:DNA duplexes using a provided poly (A) RNA
template pre-annealed to an oligo dT primer. Dissociated viral particles isolated from
plasma fractions provide reverse transcriptase in our assay and the resulting RNA-DNA
heteroduplexes formed by RT enzyme activity are stained and measured using a
fluorescent dye which is highly specific for duplex nucleic acids. Samples with greater
RT enzyme activity correspond to higher concentrations of nucleic acid heteroduplex
which give higher relative fluorescence unit (RFU) readings. Each EnzChek RT assay
batch included a Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT)
enzyme standard curve in dilutions that spanned the dynamic range of the assay and
gave a convenient way to correlate RT activity detected in patient samples to a defined
number of RT enzyme units per unit of sample. Tables 2-6 show the disease status and
pool RT enzyme activity values for breast cancer, ovarian cancer and benign disease,
and healthy normal donors, respectively. Figure 8 shows a representative line graph of
individual fraction RT tests; fractions showing peak activity (an example is indicated by
the arrow in the figure) were tested by RT-PCR. The dot plots in Figures 9-13 show the
distribution of plasma RT enzyme activity test results by pool for breast cancer, ovarian
cancer, benign ovarian disease, and normal donors, respectively. When patient sera and
tissue isolates were tested directly for RT activity, high RFU values were seen in
controls that had no RT incubation step, accounting for up to 97% of the assay signal.
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Acc. #
120
127
173
171
39
157
50
99
35
131
79
86
83

Gradient Fraction Pool RT Value
A
B
C
D
3146946
1234403
590791
391091
1690669
940418
613821
535262
959453
570692
405079
334462
892942
1237300
593728
461829
795948
819758
533416
467753
687890
762709
448197
386531
615483
533322
437016
398782
565128
395387
313325
267588
534324
514503
429078
391293
440039
410624
304537
283905
374216
681383
1106323
306653
293832
307818
265460
227706
254463
261963
192109
176000

Disease
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
DCIS
total DCIS
# DCIS positive
% DCIS positive

+ve?
+
+
+
+
+
+

+

13
7
53.8

Table 2 – Patient plasma fraction RT activity by pool and disease status - DCIS
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Acc. #
108
147
109
128
114
110
163
45
55
133
28
52
73
36
155
76
2
12
48

Gradient Fraction Pool RT Value
A
B
C
D
1663377
698919
362856
271631
1444931
630595
473537
390047
1029950
591706
579065
443621
914577
532992
416109
368317
791008
555204
376870
306360
767672
360612
269517
236009
749409
1582853
1150894
832558
680608
510478
416009
384297
677296
454960
402580
370610
616209
681671
414601
321800
605161
649789
473314
407155
591888
469422
398436
370830
546438
298224
223078
194778
542724
592988
454264
411278
528752
1008470
473398
352257
525870
382446
321858
304557
524923
361397
320211
290039
477174
396590
343956
302052
180754
154723
145897
137889

Disease
IDC
IDC
IDC
IDC
IDC
IDC
IDC
IDC
DCIS+IDC
IDC
IDC
IDC
IDC
IDC
IDC
ILC
IDC
IDC
DCIS+tubular carcinoma
total invasive cancer
# invasive cancer positive
% invasive cancer positive

+ve?
+
+
+
+
+
+
+

+

19
8
42.1

Table 3 – Patient plasma fraction RT activity by pool and disease status – invasive
breast cancer
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Acc. #
112
204
174
65
141
158
105
67
125
115
153
92

A
1628379
1203391
1038934
941650
701056
659482
598699
565812
531077
483775
478361
468215

Gradient Fraction Pool
B
C
1438226 1113414
910734
564569
545113
338341
784501
688987
568797
436871
696844
664830
770691
421033
1291063
691391
521725
364645
695919
1643799
428438
350288
1140544 1546342

D
709821
358905
437531
536367
358138
513360
314240
593853
304045
1880087
312882
936441

Disease
adenocarcinoma, IIIc
serous adenocarcinoma
GI stromal tumor
metastatic adenocarcinoma
endometrial adenocarcinoma
high grade ovarian carcinoma
mullerian tumor
high-grade serous adenocarcinoma
LMP ovarian tumor
malignant mixed mullerian tumor
papillary serous
papillary serous carcinoma
total ovarian cancer
# ovarian cancer positive
% ovarian cancer positive

+ve?
+
+
+
+
+
+
+
+
+
12
9
75

Table 4 - Patient plasma fraction RT activity by pool and disease status – ovarian cancer
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Acc. #
202
206
169
164
186
165
142
101
71

A
698314
685244
643008
602892
579883
517323
511385
494751
426943

Gradient Fraction Pool
B
C
503500
339894
408884
297672
609756
446303
1094879
631250
360603
290234
386792
297022
467847
421010
476209
323066
389099
295179

D
290460
260292
319128
458842
253426
255242
366963
284746
258782

Disease
benign control
benign cyst
benign cyst teratoma
ovarian cyst
benign teratoma
benign control
benign cystadenofibroma
teratoma control
benign control
total ovarian benign
# ovarian positive
% ovarian positive

+ve?

+

9
1
11.1

Table 5 - Patient plasma fraction RT activity by pool and disease status – ovarian benign
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Acc. #
ND 1
ND 4
ND 2
ND 6
ND 3
ND 5

Gradient Fraction Pool RT Value
A
B
C
D
348246
285439
204213
181054
376103
318805
279443
250364
440958
306814
222697
165254
310911
884544
580280
313170
641884
539045
361070
317444
286062
273739
277796
210218

Disease
total normal
# normal positive
% normal positive

+ve?

+

6
1
16.67

Table 6 – Patient plasma fraction RT activity by pool and disease status - normal
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Figure 8 Individual RT activity test – Example of individual fraction RT results from
both patient and normal donor plasma. Patient plasma fractions showing peak RT
activity (indicated by arrow) were tested by RT-PCR using K10 and K22 primers.
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Breast IDC RT Assay Values

PicoGreen (RFU)

4.0×10 0 6
3.0×10 0 6
2.0×10 0 6
1000000

D

C
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A

0

Fraction Pool
Figure 9 Dot plot of invasive breast cancer patient plasma fraction reverse transcriptase
assay results by pool.
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Breast DCIS RT Assay Values

PicoGreen (RFU)
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3.0×10 0 6
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Fraction Pool
Figure 10 Dot plot of in situ breast cancer patient plasma fraction reverse transcriptase
assay results by pool.
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Ovarian Cancer RT Assay Values
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Figure 11 Dot plot of malignant ovarian disease patient plasma fraction reverse
transcriptase assay results by pool.
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Ovarian Benign RT Assay Values
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Figure 12 Dot plot of ovarian benign disease patient plasma fraction reverse
transcriptase assay results by pool.
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Normal Donor RT Assay Values
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Figure 13 Dot plot of normal donor plasma fraction reverse transcriptase assay results
by pool.
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Because of this non-specific signal, data from direct (unfractionated) serum and tissue
tests are limited in their usefulness and therefore not shown. Isopycnic fractionation was
determined to be a crucial part of the sample prep to minimize background signal issues.
Select fractions showing high reverse transcriptase activity were used to isolate
viral RNA and perform RT-PCR using HERV-K Env type 1 and type 2 primers, as seen
in Figures 14-17. Since our vRNA template is inside of the virus, as well as the presence
of heparin which interferes with downstream RT-PCR of the plasma fractions, samples
were processed with Qiagen’s MinElute Viral RNA kit. A sample of these RT-PCR
amplicons was digested with RNase A as a control. The sample loading is as follows:
amplicon from type 1 primers without RNase treatment, amplicons from type 1 primers
with RNase treatment, and amplicons from type 2 primers without RNase treatment. The
amplicons were resolved on 1% agarose-TAE gels, stained with ethidium bromide, and
imaged. The usefulness of screening fractions for HERV-K vRNA is seriously
compromised by the fact that three out of four normal donor samples that tested negative
for reverse transcriptase, whose inclusion in the assay was intended as a negative
control, gave amplicons with type 1 primers that could be clearly ablated with RNase
treatment. Though many of the cancer patient samples also gave the proper size of
amplicons using type 1 primers, this confounding result makes interpretation of RT-PCR
experiments difficult, and suggests that screening for presence of HERV-K Env vRNA
in plasma fractions should be accomplished by another means, such as nucleic acid
sequence-based amplification (NASBA). NASBA results are not influenced by DNA
contamination of the sample and use of this method would control for patient genomic
DNA as a source of non-specific signal.
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A.

B.

Figure 14a, b Patient plasma fraction RT-PCR results using K10 and K22 primers.
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A.

B.

Figure 15a, b Patient plasma fraction RT-PCR results using K10 and K22 primers.
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A.

B.

Figure 16a, b Patient plasma fraction RT-PCR results using K10 and K22 primers.
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A.

B.

Figure 17a, b Patient plasma fraction RT-PCR results using K10 and K22 primers.
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From the samples that yielded an amplicon, specific bands were excised,
purified, and submitted for sequencing with an HERV-K Env SU-specific primer. The
reported sequences were processed by NCBI’s BLAST algorithm and the results of the
highest scoring alignments are shown in Table 7. Individual plasma fractions from
representative patients and a normal donor were selected to test for presence of HERV-K
Env SU antigen by western blotting using 6e11and anti-mouse IgG-HRP as the probe.
The results from the RT activity assay and western blot along with the measured fraction
density are compiled for these samples and shown in Figures 18-21.
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Patient #/ Disease Status

Top Scoring BLAST
Alignment

Score

E
value

Acc. Number

Acc. # 104 =
serous/high-grade serous
carcinoma
(ovarian cancer)

Human endogenous
retrovirus K115

1044

0.0

AY037929.1

Acc. # 163 =
invasive ductal carcinoma
(IDC, breast cancer)

Homo sapiens isolate T842
endogenous virus HERV-K
envelope

1450

0.0

DQ069912.1

Acc. # 155 =
invasive ductal carcinoma
(breast cancer)

Human endogenous
retrovirus K isolate HD8.13

953

0.0

EU308984.1

Acc. # 127 =
ductal carcinoma in situ
(DCIS, breast cancer)
with RNase treatment

Homo sapiens isolate HML2_3q12.3 endogenous virus
HERV-K

126

4e-26

JN675021.1

Acc. # 127 =
DCIS

Human endogenous
retrovirus K isolate HD8.5

174

2e-40

EU308977.1

Acc. # 115 =
malignant mixed mullerian
tumor
(MMMT, ovarian cancer) peak 1

Homo sapiens isolate T842
endogenous virus HERV-K
envelope

857

0.0

DQ069912.1

Acc. # 115 = MMMT
(ovarian cancer) peak 2

Homo sapiens endogenous
virus HERV-K chromosome
19

1426

0.0

JN656291.1

Acc. # 104 =
serous/high-grade serous
carcinoma
(ovarian cancer)

Human endogenous
retrovirus K clone 5b8

699

0.0

DQ360575.1

Sk-Br-3 (ATCC malignant breast
cancer cell line, positive control)

Homo sapiens isolate HML2_19q11 endogenous virus
HERV-K

695

0.0

JN675080.1

Table 7 Top-scoring BLAST alignments from sequenced RT-PCR amplicons
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Figure 18 Patient Acc. # 136 fraction density, western blot, and RT activity.
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Figure 19 Patient Acc. # 200 fraction density, western blot, and RT activity.
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Figure 20 Patient Acc. # 195 fraction density, western blot, and RT activity.
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Figure 21 Normal donor #4 fraction density, western blot, and RT activity.
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3.6 Anti-HERV-K Env SU Antibody Internalization Assay
In the realm of immunotherapeutics, the ability of the agent to be taken in beyond
the plasma membrane is a significant benefit as it can allow loading of the target cell
with various molecular cargo carried in by the internalization event, as mediated by its
antibody conjugate. We tested 6e11 for its propensity to be internalized by various
HERV-K Env positive and negative cell lines in culture using a standard internalization
assay. HERV-K Env SU on target cell surfaces was saturated with antibody during a preincubation period then washed and returned to the 37° C 5% CO2 humidified culture
incubator. The cells were processed as described in materials and methods, stained with
anti-mouse IgG-AlexaFluor 488, and imaged using confocal microscopy. Cells positive
for HERV-K Env were able to internalize significant amounts of the 6e11 within 2
hours, whereas they did not take up the IgG2a isotype control antibody under the same
conditions, as shown in Figures 22 and 23 for MDA- MB-231 and SK-BR-3,
respectively. Composite tilescans covering larger areas of the slide are included to show
uniformity of internalization across large numbers of cells. MCF-10AT did not take up
either 6e11 or the isotype control IgG2a when prepared the same way, as shown in
Figure 24. Though MCF-10AT shows intermediate HERV-K Env SU expression by
western blot, the internalization result suggests the antigen is most likely confined to the
cytoplasm or somehow lacks the epitope recognized by 6e11. All cell nuclei were
stained with DAPI as a reference.
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A.

B.

C.

Figure 22a-c (A) Internalization of 6e11 by MDA-MB-231, single frame scan, (B)
internalization of 6e11 by MDA-MB-231, 5x5 frame scans, (C) lack of internalization
of isotype control IgG2a by MDA-MB-231. Scale bar = 20μm.
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A.

B.

C.

Figure 23a-c (A) Internalization of 6e11 by SK-BR-3, single frame scan, (B)
internalization of 6e11 by SK-BR-3, 5x5 frame scan, (C) lack of internalization of
isotype control IgG2a by SK-BR-3. Scale bar = 20μ.
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A.

B.

Figure 24a-b. (A) Lack of internalization of 6e11 by MCF-10AT, single frame scan, (B)
lack of internalization of isotype control IgG2a by MCF-10AT.
Scale bar = 20μ.
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3.7 Transmission electron microscopy
Three breast cancer patient plasma gradient fractions showing high reverse
transcriptase activity as well as RT-PCR amplicons were imaged in an effort to detect
retroviral particles. Since retroviruses, which are typically sized around a hundred
nanometers in diameter, are beyond the limit of detection for visible radiation we
relied on transmission electron microscopy (TEM). Carbon-coated grids were glowdischarged and diluted plasma fraction was adsorbed directly on to the grid and
counterstained with uranyl acetate. In both patient samples tested, spherical
nanoparticles were evident, displaying size and morphology consistent with retrovirus,
as shown in Figure 25A-D and Figure 26 B. Though the size distribution of these
particles was somewhat variable, most particles observed were in the 120-140 nm range
and were similar in size and morphology in both patient plasma fractions. The presence
of similar particles from conditioned MCF-7 media suggests that even outside of the
influence of the host, cancer cells are capable of releasing virus-like particles into their
surroundings that resolve to the densities reported for retrovirus using isopycnic
separation techniques. These particles are shown in Figure 26 A.
TEM studies of 6h5-AuNP-dosed tumor xenografts clearly indicate the ability of
our antibody to bind to the surface of and deliver cargo into HERV-K+ cells from two
different cancer types (breast and pancreatic), as indicated in Figure 26 C-F. This further
illustrates the potential for our antibodies to be used as therapeutics; a tumor xenograft in
a mouse is a much better drug delivery model than simple in vitro dosing and
internalization experiments, which cannot address the complexities of pharmacokinetics.
AuNP are relatively large compared to most molecules that we would plan to conjugate
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A.

B.

Figure 25a,b. TEM. (A) Patient 74 whole mount plasma, 26,500 x and (B) 105,000 x
magnification.

C.

D.

Figure 25c,d. TEM. (C) Patient 74 whole mount plasma, 220,000 x and (D) patient 75,
135,000 x magnification.
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A.

B.

C.

D.

E.

F.

Figure 26 TEM. (A) MCF-7 confluent media fraction, 87,000 x magnification (B)
Patient 78 whole mount plasma fraction, 87,000 x magnification, (C) 6h5-AuNP in
MDA-MD-231 xenograft, 26,500 x magnification, (D) 6h5-AuNP in Panc-2 xenograft,
9,900 x magnification, (E) 16,500 x magnification, and (F) 43,000 x magnification.
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onto the antibody (ie. antineoplastic agents and radioisotopes) so there seems to be quite
a range of cargo that we could potentially deliver into HERV-K+ cells. AuNP were
chosen for this work for two reasons: 1) they are a readily seen in TEM due to their high
degree of electron scattering, and 2) they can be utilized in radiofrequency
thermoablation treatments to induce apoptosis in tissues containing these type of
nanoparticles (28), presenting a novel therapeutic modality.
3.8 Statistical analysis of RT enzyme activity data
Patient plasma RT activity results were compared across malignant cancer
patient, benign cancer patient, and normal donor samples and differences were analyzed
by t-test for statistical significance. A p-value less than 0.05 was indicative of a
significant difference. In invasive breast cancer plasma fractions, pool A was
significantly different from normal donor pool A but no others, as seen in Figure 27. For
DCIS, the only significant difference between patient and normal was found when
comparing pool D values (Figure 28). The results for ovarian cancer were much more
promising; significant differences could be found between 1) malignant and normal pool
A, 2) malignant and normal pool B, and 3) benign and normal pool A, as shown in
Figure 29. In the ovarian patients, RT activity testing was able to clearly discern samples
from malignant and benign patients compared to normal donor samples, and though
differences in breast plasma samples were not as pronounced, they were still present
compared to normal donor plasma.
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Figure 27 Patient Plasma RT assay pool value t-test for invasive breast cancer patient
vs. normal donor samples.
iA-iD are invasive breast cancer patient pools and nA-nD are normal donor pools. Star
indicates p<0.05 comparing the groups indicated.
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Figure 28 Patient Plasma RT assay pool value t-test for DCIS patient vs.
normal donor samples. dA-dD are DCIS patient pools and nA-nD are normal patient
pools. Star indicates p<0.05 comparing the groups indicated.
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Figure 29 Patient Plasma RT assay pool value t-test for malignant and benign ovarian
cancer patients compared to normal donor samples.
oA-oD are ovarian cancer plasma pools, bA-bD are benign tumor patient pools, and nAnD are normal donor plasma pools.
Stars indicate p<0.05 comparing the groups indicated.
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Chapter 4 Discussion
Evidence of HERV-K expression in human cancer was shown at the mRNA level
over a decade ago by this lab. Upon cloning and sequencing these transcripts from
various patients, it was discovered that most often multiple nonsense mutations or
deletions are present, thus preventing translation of a functional viral protein and thereby
excluding the possibility of functional viral particles. The full-length HERV-K Env SU
mRNA that was cloned to give rise to our recombinant protein K10g was isolated from a
breast cancer patient in these studies (18).
Paramount to our characterization of this emergent pathogen is a source of
reasonably consistent, high affinity and specificity antibodies against viral antigens.
Anti-HERV-K Env antibodies’ importance as diagnostic tools for oncology was first
recognized in tissue array experiments where increased intensity and distribution of IHC
staining was found to correlate strongly with refractory or advanced disease, resistance
to therapy, and overall poor patient prognosis (13). The high degree of sequence
variation inherent among retroviruses makes targeting stable, conserved epitopes with
monoclonal antibodies difficult; therefore a panel of antibodies was developed in an
effort to target multiple epitopes present on the surface domain of HERV-K Env SU.
Antibody therapeutics can induce tumor cell death in a variety of ways, such as
complement-dependent cytotoxicity, (CDC), antibody-dependent cell mediated
cytotoxicity (ADCC) (29), targeted delivery of toxic cargo (25), receptor antagonism
(30), etc. Since IgG2 antibodies show limited ability to fix complement or be recognized
by immune effector cell Fcγ receptors (31), a major objective for our antibodies was not
only to bind to molecular targets expressed on the surface of tumors but also to be
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internalized by them. This internalization event opens the possibility of delivering
various molecular cargo, including nanoparticles, isotopes, and toxins, to the cytoplasm
of those tumor cells for therapeutic purposes. Many highly potent toxins have been
developed (gelonin and Pseudomonas exotoxin (22, 23)) which exert their influence on
molecules in the cytoplasm, such as the ribosome, in order to impede vital cellular
functions. Such compounds rely on surrogate cell-binding domains such as antibodies
and synthetic antibody fragments to reach their intended sites of action and we look
forward to forming collaborations with investigators to develop and study such
compounds.
The development and studies of murine monoclonal IgGs 6h5 and 6e11 has
allowed us to study the prevalence of HERV- K Env SU protein in human cancer
samples as well as its distribution of expression and we hope to ultimately utilize these
agents to help elucidate the role of HERV-K in human tumorigenesis. 6h5 and 6e11
were chosen as lead candidates for further study and development due to their high
affinity and specificity for the HERV-K Env SU domain, thermal stability (data not
shown), high active concentration, and relative ease of production at scale. Antibodies
recognizing HERV-K Env SU have been used to detect its expression in patient tissue
samples bearing malignant neoplasia including low- and high-grade serous
adenocarcinoma, clear cell carcinoma, and low- and high-grade endometrioid cancers
whereas staining patterns of cysts and normal tissue samples show little to no expression
(18).
Production of our monoclonal antibodies using the ascites method was
advantageous for several biological and philosophical reasons. First, we have found that
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ascites fluid itself is a reasonably stable frozen storage medium from which to recover
large amounts of concentrated antibody months to years after collection. Second, we also
found that active antibody concentrations from ascites fluid were much higher compared
to antibody purified from hybridoma culture media directly (data not shown). Also,
reduced sample volumes of ascites compared to antibody purified from hybridoma
culture media directly allows reduction of reagent volumes in subsequent processing
steps, making the process more efficient and cost-effective. Total antibody yields from
ascites aliquots were typically 1 mg final purified antibody per 1 ml of frozen ascites.
Estimations of purity and activity of antibodies and synthesized molecules was
determined by western blot and/ or SDS-PAGE gel staining with coomassie brilliant
blue R250.
Thermodynamics of antigen:antibody interactions were evaluated using the
Biacore platform. Understanding the nature of the antibody interaction with its cognate
antigen is crucial; low-affinity antibodies do not typically make for good drugs since
they cannot be found interacting with the antigen as often as high-affinity antibodies do.
In the context of antibody-mediated drug delivery, low-affinity antibodies are less likely
to be found bound to the target cell and therefore will not be internalized as readily. This
becomes a bigger problem as cell surface expression of the target antigen decreases. The
result is that more antibody must be used to achieve desired effect compared to a higher
affinity conjugate. For diagnostic purposes, the problem is similar; more antibody must
be used when working with lower affinity antibodies to get the same degree of labeling
as a smaller amount of high-affinity antibody. Diagnostic tests using low affinity
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antibodies are less sensitive in general and will have more issues with non-specific
binding.
The antigen K10g was used as the immobilized ligand as it is the smaller of the
two binding partners (67 kDa for K10g vs. 150 kDa for IgG) and allowed us to use the
same sensor surfaces to evaluate all of our antigen:antibody interactions in this study. In
order for the ligand immobilization to be successful, the molecule must be attracted
electrostatically to the carboxymethyl dextran sensor surface to achieve concentration of
ligand at the sensor surface at a pH that does not compromise the potential binding sites
present on that ligand. For proteinaceous ligands, variations in unique protein pI dictate
this scouting exercise; in our case 10 mM sodium acetate pH 4.5 was chosen, as it was
the least acidic condition that gave satisfactory attraction to the sensor surface. Another
important concern for obtaining reliable SPR data is determining sensor surface
regeneration conditions. This step in the analyte injection cycle removes bound materials
that are occupying binding sites on the ligand to liberate those sites to participate in
analyte binding in the next injection cycle. A desirable regeneration condition is one that
both 1) returns the sensor surface response to nearly the baseline response seen before
the analyte injection, and 2) does not strip off or denature sufficient amounts of ligand as
to render the sensor surface unstable or unusable. None of the conditions tested were
effective at surface regeneration except for 10 mM sodium hydroxide, which did an
excellent job of both returning the sensorgram response to baseline and preserving the
fidelity of the ligand on the sensor surface. Fortunately, 6e11 was also thoroughly
removed from the sensor surface using these same conditions therefore 10 mM sodium
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hydroxide was the regenerant of choice for all subsequent kinetic and concentration
experiments using the Biacore X100.
Kinetic evaluations were performed using Biacore on low ligand density sensor
surfaces with surface densities of immobilized K10g around 200 RU. This, along with
use of relatively low antibody concentrations (3 – 48 nM) and relatively high flow rates
(30 μl/min) minimizes the effect of avidity when testing bivalent analytes such as IgG
which can result in artificially slow off-rates, confounding affinity determinations. Our
success in minimizing avidity effects experimentally is reflected by ideal χ2 fitting
statistics in all kinetic experiments. Determination of kinetic binding constants from
changes in response units at the sensor surface is defined by the following equation:
ΔR/ΔT = ka x C x (Rmax – R) – kd x R
(32) where Rmax is the maximum signal in the experiment, R is the signal for a given
injection cycle, T is time, ka is the association constant, kd is the dissociation constant,
and C is the active analyte concentration. Our kinetic data was fitted to a 1:1
(monovalent) Langmuir thermodynamic model using Biacore X100 evaluation software
and the χ2 values are at or below 1% of response maximum (Rmax) for the assay, which is
considered within the noise threshold of the instrument’s detectors and has been
informally adopted as a guideline for establishing goodness-of-fit of our experimental
data to the binding model. The Biacore X100 evaluation software allows fitting to
bivalent analyte binding models and we see little improvement of χ2 values when fitting
to these models, further indicating the 1:1 Langmuir model is appropriate. Also, in our
kinetic evaluations our uniqueness value (U-value), which is a measure of
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interdependence of the association and dissociation rates, was always below 10, well
within the acceptable range for uniqueness.
Active (binding) concentration of purified antibody was first determined using
calibration-free concentration analysis (CFCA), also on the Biacore X100 platform. This
recent feature available on newer Biacore instruments with the proper analysis software
allows determination of active protein concentration using a high-density ligand chip
(Biacore recommends immobilization densities of 5000 to 10,000 RU). The method
requires one to inject a wide range of analyte dilutions and supply a diffusion coefficient
for the molecule. The instrument injects the dilution range at two different flow rates in
an attempt to force mass transport limitations in the data. The derivation of
thermodynamic equations describing the relationship between analyte concentration,
diffusion coefficients, mass transport limitations under laminar flow, and affinity can be
found in (33) for CFCA experiments and (32) for kinetic experiments. We have found
that it is not uncommon for a given lot of antibody to be 50% active or less; as these
errors would greatly impact the quality of the kinetic binding data, which rely on correct
concentrations to produce correct kinetic constants, we have elected to employ CFCA
data to determine active antibody concentration for further kinetic experiments on these
molecules.
Western blotting results of cultured malignant and control cells lines probed for
HERV-K Env SU shows very nice correlation between disease state and HERV-K Env
expression levels. In support of our hypothesis, all breast cancer cell lines tested were
positive for HERV-K Env. The benign cell line MCF-10A was negative for HERV-K
Env and the H-Ras-transformed benign cell line MCF-10AT showed an intermediate
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expression level of HERV-K Env between cells derived from benign and malignant
cancer tissue.
Patient plasma density gradient fractions were pooled and analyzed by a
microplate-based reverse transcriptase enzyme activity assay EnzChek RT (Invitrogen).
This system relies on reverse transcriptase activity in the sample to synthesize
RNA:DNA heteroduplexes from a pre-annealed poly (A) RNA template and oligo dT
primer. The reaction products are stained with PicoGreen, a dye that is highly specific
for duplex nucleic acids. The fluorescence spectra of PicoGreen:duplex nucleic acid
show excitation and emission maxima at 503 nm and 522 nm, respectively. Since many
biological samples will show autofluorescence using these excitation and emission
wavelengths, the plates were read on the reader before and after the addition of the
reporter dye. A low baseline autofluorescence was noted from all plasma fractions that
corresponded approximately to the amount of signal seen in reverse transcriptase
negative normal donor plasma. Isopycnic density gradient fractionation of plasma was
able to resolve viral particles from bulk plasma impurities and gave useful results; this
was not the case for patient tissue isolates. Because the tissue was disrupted, clarified,
and sampled directly without density fractionation, much larger amounts of either
genomic DNA, autofluorescent debris, or both, were present in the sample. In tissue
isolates, the majority of the reverse transcriptase assay signal could be realized without
carrying out the actual RT incubation step. This was also the case when patient sera were
assayed directly (without density fractionation) with this same method; up to 97% of the
reverse transcriptase assay signal was realized without carrying out the RT incubation
step (data not shown). Of course, this is somewhat less of an issue when samples derived
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in the same way are compared to one another, for example when comparing tumor and
uninvolved tissue from the same patient, but significant confounding biases can still
exist. For example, uninvolved tissue from beyond the tumor margin may not have the
same composition or distribution of cell and tissue types as the neoplastic sample. The
malignant tissues may also have differences in tissue concentrations of autofluorescent
compounds or possibly DNA content due to hyperploidy of malignant cells. As a result,
plasma fraction RT activity results cannot be readily compared to either tissue
homogenate or serum direct test values. Comparison and statistical analysis of patient
and normal donor plasma fraction RT activity values, however, showed statistical
significance by t-test (p<0.05) in all patient groups. Once much larger patient
populations of breast, ovarian, as well as other cancer patient plasma can be screened for
RT activity to verify that these findings extend beyond the scope of this study, reverse
transcriptase enzyme activity could become a bona fide screening tool to determine or
predict patient disease state.
Reverse Transcription - Polymerase Chain Reaction was carried out on a
sampling of patient plasma density gradient fractions showing high RT activity. These
patients represent several different gynecological cancers, including malignant breast
neoplasia such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and
invasive lobular carcinoma (ILC). Malignant ovarian cancer types including serous and
high-grade serous adenocarcinoma, papillary serous carcinoma, malignant mixed
mullerian tumor (MMMT), and metastatic adenocarcinoma were also assayed. For
control purposes, we included samples from several patients bearing benign ovarian
disease as well as numerous healthy blood bank donors. Since we are attempting to
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amplify intronless retroviral elements, our primers will generate an amplicon of identical
size from either genomic DNA (from the host) or vRNA templates. Qiagen’s One-Step
RT-PCR kit was chosen for its ability to specifically amplify very small amounts of
template efficiently using a cocktail of polymerases and its high degree of sensitivity,
down to 1 pg of template. With this system, cDNA is also generated in a sequencespecific manner, minimizing the number of extraneous templates that could interfere
with the assay. One drawback, however, is that the entire process occurs in a single tube
in continuous fashion, precluding the opportunity to run a parallel control omitting the
RT reaction in the same system. In the large-scale RT-PCR screen, we chose to include
RNase A-digested vRNA template control in an attempt to account and control for
genomic DNA contamination in the sample. In this case, the digested template will show
ablation of the amplicon, indicating that the template was indeed RNA. If the after
RNase A digestion the amplicons prevails, the template was most likely host genomic
DNA. We performed a similar control using DNase I to digest possible host genomic
DNA in fractions before RT-PCR, however difficulties in deactivating the enzyme lead
to inhibition of the subsequent RT-PCR. Samples that show amplicons at the correct
molecular weight were excised and submitted for sequencing; sequencing results were
aligned to sequences deposited in PubMed using BLAST. A useful exercise would be to
identify open reading frames, mutations, and stop codons in the translated sequences and
compare findings between cancer patient, benign tumor patient, and normal samples;
more information can surely be extracted from these comparisons.
Western blotting of patient plasma gradient fractions posed unique challenges
due to the presence of iodixanol density gradient media as well as high concentrations of
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plasma protein, especially in the most dense samples, along with blood lipids. The
problem became apparent after heating in standard Laemmli reducing sample buffer,
where many times the sample would turn into either a gel or semi-solid form. Even with
increasing amounts reducing sample buffer, smearing of the samples on the blot was an
issue in preliminary attempts. After some testing, a sample buffer containing adequate
amounts of chaotrope, detergent, and reducing agent to keep the sample fully solubilized
was chosen. The final sample buffer recipe containing 6 M urea, 1% CHAPS, 2% SDS,
and 50 mM DTT was employed. Blots were probed with 6e11 primary and anti-mouse
IgG-HRP secondary antibodies. An enhanced chemiluminescent HRP substrate (Western
Lightening Plus, Perkin Elmer) was used to develop the blots and light emission was
captured in a dark room using BioMax Light blue-sensitive double emulsion ECL
imaging film at multiple exposure times. A lane containing recombinant K10g was
included to ascertain antibody binding specificity as was a lane of molecular weight
standard (Precision Plus Kaleidoscope, Bio-Rad). Bands corresponding to HERV-K Env
SU were detected in lanes where fraction density matched that reported for retrovirus,
around 1.18. Western blot data, reverse transcriptase activity, and fraction density were
in very good agreement for all patients tested.
An antibody internalization assay was carried out in order to determine our
monoclonal antibodies’ potential for binding to and delivering various molecular cargo
into cells expressing HERV-K Env on their cell surface. Use of mountants with
relatively high, matched indices of refraction help to minimize spherical aberrations in
the image; pure glycerol has an index of refraction around 1.47, closely matching that of
the coverglass and immersion oil used (borosilicate glass = 1.51 and Zeiss Immersol
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518F = 1.52). In order to acquire confocal images, detection pinhole apertures for each
channel were set at 1 airy unit, an optimal diameter for best image signal-to-noise ratio
and an ideal compromise between resolution and signal intensity. At 1 airy unit the
diameter of the emission pinhole matches that of the airy disk generated by diffraction of
the point light source originating within the sample and the actual 1 airy unit diameter of
the pinhole is determined by the wavelength of the diffracted radiation and the numerical
aperture of optical components in the microscope. Based on Rayleigh’s criterion, the
critical determinant of the scale at which features can be spatially resolved is determined
largely by the wavelength of radiation used in the imaging process. For circular
apertures the maximum theoretical resolution using visible radiation (using 550 nm
average λ for visible radiation) is around 275 nm, much greater than the size of our virus.
In order to directly visualize viral particles from patient plasma density gradient
fractions, we utilized transmission electron microscopy (TEM).
Betaretroviral particles have been reported in previous efforts to be at or around
100 nm in diameter (14). TEM can generate an electron beam at 80 kv acceleration with
sufficiently short wavelength to readily image structures at nanometer scale, well within
the range of our virus. In retrospect, early attempts at adsorbing viral particles onto
carbon-coated grids were probably futile, since the carbon layer is hydrophobic and
would not tend to bind materials whose nature is hydrophilic. Consultation with an
expert in the field (Dr. Dwight Romanovicz, University of Texas at Austin Institute of
Cellular and Molecular Biology Microscopy Core) lead to the notion of glowdischarging the carbon layer to impart upon it a temporary charge. Immediately after the
glow discharge treatment the diluted plasma fraction was adsorbed and counterstained; it

82

was this processing that allowed us to capture images of a nanoparticle with size,
staining, and morphology similar to that reported for retrovirus. That these particles were
identified in cancer patient density gradient fractionated plasma samples with high
reverse transcriptase activity, RT-PCR amplicons for HERV-K Env SU, and density
equal to that reported for retrovirus, lends credence to the notion that these nanoparticles
are indeed HERV-K. At lower magnifications, the relative abundance of particles can be
seen. There appears to be range of sizes, suggesting varying degrees of virus maturity in
the same patient.
TEM images of immune-compromised mice bearing xenograft tumors dosed
with 6h5-AuNP show internalization of large amounts of AuNP into those tissues.
Tumor-bearing mice are a significant improvement over in vitro dosing experiments as
the distribution, metabolism, and elimination aspects of pharmacokinetics are in effect
much as they would be in an actual patient in the clinic. Abnormalities in tumor
vasculature play a major role in the uptake and retention of drugs and nanoparticles and
it gives us great hope for the potential of anti-HERV-K Env SU-binding antibodies and
their conjugates as therapeutics to see such robust delivery of materials to HERV-K+ cell
types. These data were generated for demonstrative purposes only in a pilot study;
further work will need to be done with isotype control antibody-AuNP conjugates and
AuNP only to check for non-targeted uptake of AuNP into HERV-K+ tissues. The pilot
study also included HERV-K+ pancreatic cancer, which is why this cancer type was
included in a text focusing on breast and ovarian cancers, but the results were excellent
and warrant further studies carried out with the proper controls mentioned above.
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Chapter 5 Conclusion and Further Studies
5.1 Conclusion
Profiling patient and donor sample reverse transcriptase activity proved to be
useful marker for determining patient disease status, especially for ovarian cancers.
Confirmation of the presence of plasma reverse transcriptase activity can be used to
predict disease, though absence of activity is somewhat indeterminate.
Our antibodies recognizing HERV-K Env SU domain show great promise as
both diagnostic and therapeutic agents in oncology. Their high specificity and sensitivity
for HERV-K Env SU make them excellent candidate diagnostic tools and their
propensity for internalization into tumor cells expressing HERV-K Env on their surface
make them attractive candidates for further developmental efforts.
5.2 Future Studies
A survey of patient plasma sample reverse transcriptase activity from other
cancer types, such a melanoma, hepatic, pancreatic, and lung cancer, would be useful to
determine how broadly-applicable this screening strategy would be for other disease
types. Thorough pre-screening of patients for viral pathogens would be highly
advantageous to minimize confounding results related to the possible presence of viruses
that are not HERV-K.
Cloning, humanization, and affinity maturation of our murine anti-HERV-K Env
SU binding sequences could enable the development of first-in-class
immunotherapeutics. Conjugation of these engineered antibodies to chemotherapy
agents, prodrugs, radioisotopes, fluorescent dyes, toxin fragments, or enzymes would
only increase the utility and potential of these molecules in the laboratory and clinic.
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